Polycythemia Vera (PV): Update on Emerging Treat... - MPN Voice

MPN Voice

10,445 members14,398 posts

Polycythemia Vera (PV): Update on Emerging Treatment Options

Manouche profile image
5 Replies

« Currently, in PV treatment, several molecules have been tested or are under investigation. At present, the drug that has shown the most encouraging results is givinostat. »

pubmed.ncbi.nlm.nih.gov/337...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
5 Replies
Bluetop profile image
Bluetop

Thanks for posting. I had not picked up on givinostat.

Lena70 profile image
Lena70 in reply to Bluetop

You might be interested in this article. I can't help but feel hopeful.

pubmed.ncbi.nlm.nih.gov/326...

Givinostat: an emerging treatment for polycythemia vera

The full-text isn't available, but the publisher provides a good summary of the article here:

tandfonline.com/doi/abs/10....

Bluetop profile image
Bluetop in reply to Lena70

Thanks. I does seem there is developing interest in this treatment

Lena70 profile image
Lena70

I'm reading about givinostat and if it helps with the itchiness, I will be delighted. I am so itchy today!

BioUnicorn profile image
BioUnicorn

Thanks for posting! Just diagnosed PV last month. Was put on hydroxyurea.

You may also like...

Update on my polycythemia vera diagnosis

I have received my hospital consultant letter from the GP and I'm still trying to understand the...

Increased Besremi Dose to Be Studied for Polycythemia Vera Treatment

patients in the utility of the treatment to manage this chronic cancer »...

Dr Silver updating re PV, risk criteria and best treatment options

Quite long but if you have PV, well worth watching. https://youtu.be/ZlqWabW4wTE The slide at the...

Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management

history. Additional Treatment Considerations At the present time, we do not consider a...

Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera

Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option...